EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space

Yulia Dyachkova, Cornelia Dunger-Baldauf iD, Nathalie Barbier, Jenny Devenport iD, Stefan Franzén, Gbenga Kazeem, Thomas Künzel, Pierre Mancini, Giacomo Mordenti, Knut Richert, Antonia Ridolfi, Daniel Saure

Pharmaceutical Statistics · 2024

DOI: 10.1002/pst.2412 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Statistics, 2024. Verfasst von Yulia Dyachkova und 11 weiteren Autor:innen. Beteiligte Einrichtung: Merck Healthcare KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: Drug Development, Clinical Trials as Topic, Research Design. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 61 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Single‐arm trials (SATs), while not preferred, remain in use throughout the drug development cycle. They may be accepted by regulators in particular contexts (e.g., in oncology or rare diseases) when the potential effects of new treatments are very large and placebo treatment is unethical. However, in the postregulatory space, SATs are common, and perhaps even more poorly suited to address the questions of interest. In this manuscript, we review regulatory and HTA positions on SATs; challenges posed by SATs to address research questions beyond regulators, evolving statistical methods to provide context for SATs, case studies where SATs could and could not address questions of interest, and communication strategies to influence decision making and optimize study design to address evidence needs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentClinical Trials as TopicResearch DesignHumansDecision Making

Stichwörter der Autor:innen

causal inferenceprincipled decision‐makingsingle‐arm trial

Autor:innen und Institutionen

  • Merck Healthcare KGaA, Darmstadt, Germany.
  • Novartis AG, Basel, Switzerland.
  • F Hoffman-La Roche, Basel, Switzerland.
  • AstraZeneca UK Ltd, Cambridge, UK.
  • GlaxoSmithKline, Stevenage, UK.
  • Sanofi, Paris, France.

ORCID-Profile: Cornelia Dunger-Baldauf, Jenny Devenport

Zitieren

APA

Dyachkova, Y., Dunger-Baldauf, C., Barbier, N., Devenport, J., Franzén, S., Kazeem, G., Künzel, T., Mancini, P., Mordenti, G., Richert, K., Ridolfi, A., & Saure, D. (2024). Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space. Pharmaceutical Statistics. https://doi.org/10.1002/pst.2412

Vancouver

Dyachkova Y, Dunger-Baldauf C, Barbier N, Devenport J, Franzén S, Kazeem G, et al. Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space. Pharmaceutical Statistics. 2024. doi:10.1002/pst.2412

BibTeX
@article{Dyachkova2024,
  author = {Dyachkova, Yulia and Dunger-Baldauf, Cornelia and Barbier, Nathalie and Devenport, Jenny and Franzén, Stefan and Kazeem, Gbenga and Künzel, Thomas and Mancini, Pierre and Mordenti, Giacomo and Richert, Knut and Ridolfi, Antonia and Saure, Daniel},
  title = {Do You Want to Stay Single? Considerations on Single‐Arm Trials in Drug Development and the Postregulatory Space},
  journal = {Pharmaceutical Statistics},
  year = {2024},
  doi = {10.1002/pst.2412}
}
Kostenlos starten →